Continued axillary sampling is unnecessary and provides no further information to sentinel node biopsy in staging breast cancer

Gui, Gerald; Reichert, R.; Ward, Ann; Lakhani, Sunil R.; Osin, Peter; Nerurkar, Ashutash; A’Hern, Roger; Benson, Keith G.; Underwood, S. R.

doi:10.1016/j.ejso.2005.04.014

Cited by 15 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our higher FNR mainly resulted from the relatively high number of T2 cases. Some series have had a FNRs of 0-0.5% [9,16], and some others between 2.7% and 17% [8,14,17-20]. The higher FNR in our T2 cases emphasizes the importance of tumor size.…”

Section: Discussionmentioning

confidence: 71%

Tumor Characteristics Influencing Non-Sentinel Lymph Node Involvement in Clinically Node Negative Patients with Breast Cancer

et al. 2011

View full text Add to dashboard Cite

PurposeThe negative sentinel lymph node (SLN) biopsy avoids conventional axillary dissection in patients with breast cancer with clinically negative axilla. Despite negative SLN, there is a risk of leaving involved non-SLN behind in the axilla. We investigated the predictive power of tumor characteristics for non-SLN metastasis.MethodsLymphatic mapping with blue dye method for SLN biopsy and level 1-2 axillary dissections were performed to establish axillary status in 59 patients with T1 and T2 breast cancer and clinically negative axilla. Tumor's characteristics were histopathologically established to assess their association with non-SLN metastasis.ResultsThe axilla was malignant in 23 (39%) patients. The SLN alone was metastatic in 10, both SLN and non-SLN in 9, and non-SLN alone in 4 (7%) patients. The false negative rate for SLN biopsy was 10% in our series. The rate of positive non-SLN was found as 0% in T1a-b, 19% in T1c, and 40% in T2 tumors (p=0.035). Lymphovascular invasion was positive in 14 (61%) patients with axillary metastasis (p<0.001), and in 10 (77%) patients with non-SLN involvement (p<0.001).ConclusionWe concluded that there was a small risk of involved non-SLN despite negative SLN. Tumor size (near or greater than 2 cm) was significantly associated with non-SLN metastasis. Peritumoral lymphovascular invasion was a positive predictor of the metastatic involvement in non-SLNs.

show abstract

Section: Discussionmentioning

confidence: 71%

Tumor Characteristics Influencing Non-Sentinel Lymph Node Involvement in Clinically Node Negative Patients with Breast Cancer

et al. 2011

View full text Add to dashboard Cite

show abstract

“…20,21 Lymph nodes that can be palpated intraoperatively through the incision of the SN biopsy and are felt to be suspicious should be harvested and regarded as SN. 2,22,23 Axillary Ultrasound…”

Section: Palpable Lymph Nodesmentioning

confidence: 99%

Additional Tracer Injection to Improve the Technical Success Rate of Lymphoscintigraphy for Sentinel Node Biopsy in Breast Cancer

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Furthermore, some studies showed that four lymph nodes may be dissected as a supplement to SLNB to reduce the false negative rate [ 27 ]. However, the results reported in the literature are inconsistent [ 28 ]. Numerous studies recently addressed ultrasound-guided axillary sampling as an alternate/additional staging procedure to improve the accuracy of SLNB [ 29 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

Improved false negative rate of axillary status using sentinel lymph node biopsy and ultrasound-suspicious lymph node sampling in patients with early breast cancer

Wang

Dong

et al. 2015

BMC Cancer

View full text Add to dashboard Cite

BackgroundThe false negative rate of sentinel lymph node biopsy (SLNB) is 5-10%, and results in improper patient management. The study was to assess the value of ultrasound-suspicious axillary lymph node biopsy (USALNB) in patients with early breast cancer, and to compare SLNB combined with USALNB (SLNB + USALNB) with SLNB alone.MethodsFrom January 2010 to July 2013, 216 patients with early breast cancer were enrolled consecutively at the Department of Breast and Thyroid Surgery, Qianfoshan Hospital, Shandong University. All patients underwent wire localization of the suspicious node by color Doppler ultrasonography, followed by SLNB 2–3 hours later, suspicious node lymphadenectomy, and level ≥ II axillary dissection (as the gold standard). The predictive values of node status between SLNB + USALNB and SLNB alone were compared.ResultsThe success rate of SLNB was 99.1% (214/216). After axillary dissection, 71 patients were confirmed with axillary lymph node metastases by pathological examinations. Eight false negatives were observed using SLNB alone, resulting in sensitivity of 88.7%, specificity of 100%, false negative rate of 11.3%, and false positive rate of 0% in predicting the axillary node status. SLNB + USALNB resulted in sensitivity of 97.2%, specificity of 100%, false negative rate of 2.8%, and false positive rate of 0%. The false negative rate of SLNB + USALNB was significantly different from that of SLNB alone (P = 0.031).ConclusionsSLNB + USALNB seems to be a low-risk procedure that might be useful in reducing the false negative rate of SLNB, improving the accuracy of axillary nodes evaluation in early breast cancer.

show abstract

Continued axillary sampling is unnecessary and provides no further information to sentinel node biopsy in staging breast cancer

Cited by 15 publications

References 29 publications

Tumor Characteristics Influencing Non-Sentinel Lymph Node Involvement in Clinically Node Negative Patients with Breast Cancer

Tumor Characteristics Influencing Non-Sentinel Lymph Node Involvement in Clinically Node Negative Patients with Breast Cancer

Additional Tracer Injection to Improve the Technical Success Rate of Lymphoscintigraphy for Sentinel Node Biopsy in Breast Cancer

Improved false negative rate of axillary status using sentinel lymph node biopsy and ultrasound-suspicious lymph node sampling in patients with early breast cancer

Contact Info

Product

Resources

About